Polarean Expands Xenon MRI Platform for Pharma Research

Polarean Imaging ( (GB:POLX) ) just unveiled an announcement.

Polarean Imaging has expanded its Xenon MRI imaging platform to support pharma-sponsored research, partnering with VIDA Diagnostics. This expansion includes a new service model that enables the use of Xenon MRI in a multicenter study by a global pharmaceutical collaborator, focusing on an investigational lung therapy. The collaboration aims to streamline pulmonary drug development by providing high-quality imaging controls, potentially reducing patient numbers and accelerating drug time-to-market. This initiative underscores the growing recognition of Xenon MRI as a valuable tool in respiratory medicine, enhancing Polarean’s industry positioning and offering strategic growth opportunities.

More about Polarean Imaging

Polarean Imaging is a medical imaging technology company that specializes in advanced MRI for lung function. It focuses on revolutionizing pulmonary medicine by providing direct visualization of lung function using its FDA-approved hyperpolarized Xenon MRI contrast agent, XENOVIEW®. The company aims to address the global unmet medical needs of patients with chronic respiratory diseases through innovative, non-invasive, and radiation-free imaging solutions. Founded in 2012, Polarean operates from Durham, NC, and London, UK.

YTD Price Performance: 40.0%

Average Trading Volume: 18,670

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $19.08M

Learn more about POLX stock on TipRanks’ Stock Analysis page.